Recife

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Lupus (SLE)3 trials
• Heart failure1 trial
• IgA nephropathy1 trial
• Lung cancer1 trial
• Sickle cell disease1 trial

Phase

• Phase 35 trials
• Phase 21 trial
• Phase 41 trial

Status

• Active, not recruiting3 trials
• Completed2 trials
• Recruiting2 trials

Lead sponsor

• Novartis Pharmaceuticals7 trials

Running trials

• Recruiting

  A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

  NCT07146906· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

  NCT06711887· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

  NCT05639114· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

  NCT05126277· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

  NCT03814746· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• IgA nephropathy1 recruiting
• Lupus (SLE)1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

  NCT04023227· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

  NCT01828099· Phase 3· Novartis Pharmaceuticals· Source